Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Maze Therapeutics, Inc.NASDAQ: MAZE

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin at -121.0%

Net margin was -121.0% in Q1 FY2026. On a trailing-twelve-month basis it was -612.7%, down 643.7 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-121.0%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
-612.7%-643.7 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2024
31.2%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How MAZE compares with its peers on the latest reported figures

  • MAZE's LTM Mar 2026 net margin of -612.7% is the 5th highest of the 7 companies compared; the peer median is -40.0%.
  • Its year-over-year change of -643.7 pp is the 6th highest of 7, against a peer median of +1.5 pp.
MAZE Competitors Peer median
Net Margin for MAZE and competitors
Company Period LTM level YoY 3-year change
PTCTPTC Therapeutics, Inc.LTM Jun 2026-3.8% -39.5 pp+119.4 pp
ARDXArdelyx, Inc.LTM Mar 2026-13.6% +1.3 pp+113.7 pp
TVTXTravere Therapeutics, Inc.LTM Sep 2026-18.7% +1.7 pp+249.2 pp
SEPNSepterna, Inc.LTM Sep 2026-61.3% +205.5 pp—
MAZEMaze Therapeutics, Inc.LTM Mar 2026-612.7% -643.7 pp—
BIOABioAge Labs, Inc.LTM Mar 2026-871.8% +4024.5 pp—
IVAInventiva S.A.FY2025-7587.8% -5585.1 pp-7142.2 pp
DMACDiaMedica Therapeutics Inc.FY2025— ——
Peer median (excluding MAZE) -40.0%+1.5 pp+116.6 pp

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.